| ¿µ¹® | amino acids | ÇÑ±Û | ¾Æ¹Ì³ë»ê |
|---|---|---|---|
| ¼³¸í | ¾Æ¹Ì³ë±â(£NH3)¿Í Ä«¸£º¹½Ç±â(£COOH)¸¦ °¡Áö°í ÀÖ´Â ¸ðµç À¯±â¹°Áú. ´Ü¹éÁúÀ» ÀÌ·ç´Â ±âº»´ÜÀ§°¡ µÈ´Ù. Áï ´Ü¹éÁúÀº ¾Æ¹Ì³ë»êÀÌ ¿¬°áµÇ¾î¼ ÀÌ·ç´Â °ÍÀÌ´Ù. ÀÎü¿¡¼´Â ¾Æ¹Ì³ë»êÀÌ ´Ü¹éÁúÀÇ ±âº»´ÜÀ§°¡ µÇ´Â °Í¿Ü¿¡ ½Å°æ¼¼Æ÷¿Í ½Å°æ¼¼Æ÷°¡ ¼·Î ¿¬¶ôÀ» ÁÖ°í ¹Þ´Âµ¥ ¾²ÀÌ´Â ½Å°æÀü´Þ¹°Áú·Î¼ÀÇ ¿ªÇÒµµ ÇÑ´Ù. »ç¶÷ÀÇ ´Ü¹éÁúÀº 20°¡ÁöÀÇ ¾Æ¹Ì³ë»êÀ¸·Î ±¸¼ºµÈ´Ù. Áï »ç¶÷¿¡ ÀÖ¾î¼ ´Ü¹éÁúÀ» ÇÕ¼ºÇÏ´Â µ¥´Â 20°¡ÁöÀÇ ¾Æ¹Ì³ë»êÀÌ ÇÊ¿äÇÏ´Ù. ¿©±â¿¡¼ 11°¡Áö´Â ÀÎü³»¿¡¼ Á÷Á¢ ÇÕ¼ºÇÒ ¼ö ÀÖÁö¸¸ ³ª¸ÓÁö 9°¡Áö´Â ÇÕ¼ºÇÒ ¼ö ¾ø°í ¹Ýµå½Ã À½½Ä¹°¿¡¼ ¼·ÃëÇØ¾ß ÇÑ´Ù. À̰ÍÀ» Çʼö¾Æ¹Ì³ë»êÀ̶ó°í ÇÑ´Ù. |
||
| VLCFA | Very Long Chain Fatty Acids |
|---|---|
| TFA | total fatty acids; transverse fascicular area; triangular fibrocartilage; trifluoroacetic acid |
| PGA1-3 | prostaglandins A1 to A3 |
| PGE, PGE1, | PGE2 prostaglandins E, E1, E2 |
| PGF, PGF1, | PGF2 prostaglandins F, F1, F2 |
| LCP | Long Chain Polyunsaturated fatty acids |
|---|---|
| LCFA | Long chain fatty acids |
| MCFA | Medium-chain fatty acids |
| MUFA | Monounsaturated fatty acids |
| SCFA | Short Chain Fatty Acids |
| monounsaturated fatty acids | A fatty acid chain with at least two empty spaces that could be hydrogenated (have a hydrogen atom added). Saturated (hydrogenated) fatty acids are a greater health risk for the development of atherosclerotic vascular disease. (27 Sep 1997) |
|---|---|
| saturated fatty acids | In eukaryotic membranes refers to stearic, palmitic and myristic acids, that are linear aliphatic chains with no double bonds. Prokaryotes have numerous branched chain saturated fatty acids. (18 Nov 1997) |
| omega 3 fatty acids | A class of fatty acids that have a double bond three carbons from the methyl moiety; reportedly, they play a role in lowering cholesterol and LDL levels. Synonym: omega-3 fatty acids. (05 Mar 2000) |
| fatty acids | Organic, monobasic acids derived from hydrocarbons by the equivalent of oxidation of a methyl group to an alcohol, aldehyde, and then acid. Fatty acids are saturated and unsaturated (fatty acids, unsaturated). (12 Dec 1998) |
| fatty acids, essential | Fatty acids that cannot be synthesised by the human body and must be obtained from dietary sources, e.g., linoleic acids and linolenic acids. (12 Dec 1998) |
| fatty acids, monounsaturated | Fatty acids which are unsaturated in only one position. (12 Dec 1998) |
| fatty acids, nonesterified | The fraction of plasma fatty acids that are not in the form of glycerol esters. They are also called free fatty acids, but this is a misnomer because they are transported complexed with albumin. (12 Dec 1998) |
| fatty acids, omega-3 | A group of fatty acids, often of marine origin, which have the first unsaturated bond in the third position from the omega carbon. These fatty acids are believed to reduce serum triglycerides, prevent insulin resistance, improve lipid profile, prolong bleeding times, reduce platelet counts, and decrease platelet adhesiveness. (12 Dec 1998) |
| fatty acids, unsaturated | Fatty acids containing one (monounsaturated) or multiple (polyunsaturated) double bonds. They predominate in most plant-derived fats. The number and position of each double bond can be specified, as in the systematic names, or the position of the double bond closest to the methyl group (omega) terminus can be specified to denote functional subdivisions of the overall group, e.g., omega-3 fatty acids. The numbers and positions of the double bonds have been linked to effects on plasma lipid, triglyceride, and cholesterol levels. (12 Dec 1998) |
| fatty acids, volatile | Short-chain fatty acids of up to six carbon atoms in length. They are the major end products of microbial fermentation in the ruminant digestive tract and have also been implicated in the causation of neurological diseases in humans. (12 Dec 1998) |
| prostaglandins | A group of compounds derived from unsaturated 20-carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase pathway. They are extremely potent mediators of a diverse group of physiological processes. (12 Dec 1998) |
| prostaglandins a | (13e,15s)-15-hydroxy-9-oxoprosta-10,13-dien-1-oic acid (pga(1)); (5z,13e,15s)-15-hydroxy-9-oxoprosta-5,10,13-trien-1-oic acid (pga(2)); (5z,13e,15s,17z)-15-hydroxy-9-oxoprosta-5,10,13,17-tetraen-1-oic acid (pga(3)). A group of naturally occurring secondary prostaglandins derived from pge. Pga(1) and pga(2) as well as their 19-hydroxy derivatives are found in many organs and tissues. (12 Dec 1998) |
| prostaglandins a, synthetic | Analogs or derivatives of prostaglandin a that do not occur naturally in the body. They do not include the product of the chemical synthesis of hormonal pga. (12 Dec 1998) |
| prostaglandins b | Physiologically active prostaglandins found in many tissues and organs. They are potent pressor substances and have many other physiological activities. (12 Dec 1998) |
| prostaglandins d | Physiologically active prostaglandins found in many tissues and organs. They show pressor activity, are mediators of inflammation, and have potential antithrombotic effects. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|